mQβ Vaccine Platform

About Iaso Therapeutics

Iaso Therapeutics is a private, preclinical-stage biotech founded in 2020 and headquartered in Cambridge, Massachusetts, with operations also noted in East Lansing, Michigan. The company's core asset is a disruptive synthetic vaccine platform based on a mutant Qβ VLP carrier, designed for rapid design-to-clinic timelines and superior immunogenicity compared to traditional carrier proteins. Iaso is pre-revenue and is advancing its platform technology, with an initial focus on infectious disease vaccines, supported by entities like the National Science Foundation.

Therapeutic Areas